Skip to main content
. 2023 Jan 12;28(2):783. doi: 10.3390/molecules28020783

Table 4.

The predicted ADMET characteristics for venetoclax and the saquayamycin F (NPA002200).

Compound Name/Code Absorption
(A)
Distribution (D) Metabolism
(M)
Excretion
(E)
Toxicity
(T)
Caco2 Permeability Human Intestinal Absorption (HIA) Log BB CYP3A4 Inhibitor/Substrate Total Clearance AMES Toxicity
Venetoclax 0.847 100 –1.9 Yes –0.096 No
Saquayamycin F (NPA002200) 0.271 80.9 0.27 Yes –0.196 No